Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on invested capital (ROIC) is N/A as of Tuesday, October 6, 2026.
RETURN ON INVESTED CAPITAL (ROIC)
N/A
Scribe Therapeutics Inc.
Market Cap
$267.65M
Return on Invested Capital (ROIC)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$269.06M
Return on Invested Capital (ROIC)
-59.50%
TTM Avg
-188.11%
3Y Avg
-308.62%
5Y Avg
-250.56%
Market Cap
$265.07M
Return on Invested Capital (ROIC)
-15.00%
TTM Avg
-11.69%
3Y Avg
-3.29%
5Y Avg
-2.92%
Market Cap
$270.52M
Return on Invested Capital (ROIC)
-37.64%
TTM Avg
-32.22%
3Y Avg
-29.09%
5Y Avg
-21.19%
Market Cap
$270.62M
Return on Invested Capital (ROIC)
-31.62%
TTM Avg
-73.81%
3Y Avg
-69.44%
5Y Avg
-42.80%
Market Cap
$264.16M
Return on Invested Capital (ROIC)
-43.56%
TTM Avg
-66.27%
3Y Avg
-114.94%
5Y Avg
-104.61%
Market Cap
$271.35M
Return on Invested Capital (ROIC)
-48.92%
TTM Avg
-66.11%
3Y Avg
-56.53%
5Y Avg
-47.58%
Market Cap
$262.74M
Return on Invested Capital (ROIC)
-170.19%
TTM Avg
-56.97%
3Y Avg
-50.85%
5Y Avg
-45.83%
Market Cap
$263.41M
Return on Invested Capital (ROIC)
-42.92%
TTM Avg
-30.10%
3Y Avg
-80.25%
5Y Avg
-64.52%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Scribe Therapeutics Inc. (SCTX) | $267.65M | N/A | N/A | N/A | N/A |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $269.06M | -59.50% | -188.11% | -308.62% | -250.56% |
| OraSure Technologies, Inc. (OSUR)vs › | $265.07M | -15.00% | -11.69% | -3.29% | -2.92% |
| Treace Medical Concepts, Inc. (TMCI)vs › | $270.52M | -37.64% | -32.22% | -29.09% | -21.19% |
| SAB Biotherapeutics, Inc. (SABS)vs › | $270.62M | -31.62% | -73.81% | -69.44% | -42.80% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $264.16M | -43.56% | -66.27% | -114.94% | -104.61% |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $271.35M | -48.92% | -66.11% | -56.53% | -47.58% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $262.74M | -170.19% | -56.97% | -50.85% | -45.83% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $263.41M | -42.92% | -30.10% | -80.25% | -64.52% |
| Fate Therapeutics, Inc. (FATE)vs › | $271.10M | -58.72% | -52.25% | -49.23% | -41.07% |
ROIC
N/A
ROE
N/A
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
